Research Summary

2026 Dyslipidemia Guideline Expands US Statin Eligibility

Edited by:
Ashton L. Stahl

Key Highlights

  • An estimated 87.5 million US adults ages 30–79 qualify for primary prevention statins under the 2026 guideline, including 21.5 million newly eligible adults.
  • Eligibility includes more than 93% of adults aged 70–79 years and 85% of those aged 60–69 years.
  • Newly eligible adults were generally younger and had lower estimated cardiovascular risk than previously eligible adults.

The 2026 American Heart Association/American College of Cardiology/multisociety dyslipidemia guideline expands primary prevention statin eligibility to an estimated 21.5 million additional US adults, according to a study published in JAMA. Overall, 87.5 million adults—56.6% of the population studied—would qualify under the updated recommendations.

The study assessed the population impact of new recommendations for estimating atherosclerotic cardiovascular disease (ASCVD) risk and identifying candidates for statin therapy. Its primary outcome was the change in eligibility under the 2026 guideline compared with the 2018 lipid guideline.

Researchers analyzed a nationally representative, cross-sectional sample from the National Health and Nutrition Examination Survey collected between 2017 and 2023. Participants were nonpregnant adults aged 30–79 years without known ASCVD. Analyses were conducted from March through May 2026.

The sample included 4,366 participants, representing an estimated 154.5 million US adults after weighting. The weighted mean age was 51 years, and 52% were female.

Study Findings

The estimated proportion eligible for statins under the 2026 guideline was 56.6% (95% CI, 54.2%–58.9%), including 13.9% (95% CI, 12.5%–15.5%) who were newly eligible. Eligibility varied by age: more than 93% of adults aged 70–79 years and 85% of those aged 60–69 years qualified, compared with 11% of adults aged 30–39 years. Newly eligible individuals had a mean estimated 10-year ASCVD risk of 3.1% (95% CI, 2.7%–3.5%), compared with 6.1% (95% CI, 5.8%–6.4%) among previously eligible individuals.

Within the weighted sample, 17.8% reported taking statins, while 5.5% had untreated low-density lipoprotein cholesterol below 70 mg/dL. Another 8.6% met eligibility criteria independent of ASCVD risk estimation because of low-density lipoprotein cholesterol of at least 190 mg/dL, diabetes, or chronic kidney disease. The remaining 68% met criteria for using ASCVD risk estimation to guide statin decisions.

Clinical Implications

According to the study authors, the updated guideline substantially broadens the US population recommended for primary prevention statin therapy, with the expansion predominantly involving lower-risk individuals. Their findings characterize both the overall increase in eligibility and the younger, lower-risk profile of newly eligible adults.

Expert Commentary

“The 2026 dyslipidemia guideline substantially expands the US population recommended for primary prevention statin therapy, predominantly in lower-risk individuals,” the researchers concluded.

Reference

Anderson TS, Wilson LM, Sussman JB. Implications of the 2026 dyslipidemia guideline for primary prevention statin therapy. JAMA. 2026;336(7):557-564. doi:10.1001/jama.2026.11246